How Rescheduling Could Supercharge Cannabis Industry Growth
When President Donald Trump signed the executive order moving cannabis to a less restrictive schedule, the $32 billion legal U.S. cannabis market gained immediate relief from Section 280E of the Internal Revenue Code. That tax provision had forced businesses to pay federal income taxes on gross revenue rather than net profit, squeezing cash flow and limiting reinvestment. Analysts note that lifting 280E could cut effective tax rates by as much as 70 % for multistate operators (MSOs), freeing capital for expansion, hiring, and product development.
Industry leaders say the change also lowers borrowing costs. With cannabis no longer classified as a Schedule I substance under federal law, banks are more willing to extend lines of credit and offer traditional financing. This shift is expected to attract institutional investors who have hesitated due to regulatory uncertainty and the lack of clear accounting standards.
For Ascend Wellness Holdings, a vertically integrated MSO operating in Illinois, Michigan, Ohio, Massachusetts, New Jersey, Pennsylvania and Maryland, CEO Sam Brill sees the rescheduling as a catalyst for rapid retail growth. Brill plans to open new dispensaries in additional states and pursue strategic acquisitions that complement the company’s existing footprint. He also anticipates that customers will soon be able to use credit cards at point‑of‑sale terminals, a change he calls “a game changer” that will increase basket sizes and streamline transactions.
MariMed, based in Massachusetts, echoes this optimism. CEO Jon Levine explains that eliminating the 280E burden will improve cash flow, allowing the company to accelerate its expansion into new markets and explore product lines that could be reimbursed through Medicare and Medicaid programs. “We weren’t looking at CBD only, but this gives us the opportunity to help people who can use Medicare and Medicaid,” Levine said.
Meanwhile, Curio Wellness in Maryland is positioning itself to capitalize on the scientific opportunities that rescheduling brings. Co‑founder Wendy Bronfein notes that the company’s facilities were designed with future FDA oversight in mind, and now the evolving conversation around minor cannabinoids opens a path for clinical‑grade products that could bypass traditional dispensary channels. Curio’s scientific advisory board, chaired by Dr. David Casarett of Duke University, welcomed the executive order, stating that the move creates a “more credible foundation for medical cannabis research, clinical development and regulatory clarity.”
Subscribe to the MJBiz Factbook
Exclusive industry data and analysis to help you make informed business decisions and avoid costly missteps. All the facts, none of the hype.
What you will get:
- Monthly and quarterly updates, with new data & insights
- Financial forecasts + capital investment trends
- State-by-state guide to regulations, taxes & market opportunities
- Annual survey of cannabis businesses
- Consumer insights
- And more!
Green Dot Labs, a Colorado‑based testing and manufacturing firm, views the policy shift as a milestone after more than a decade of operating under a patchwork of state laws and federal ambiguity. CEO Alana Malone says the change begins to dismantle long‑standing obstacles such as limited access to banking and excessive tax burdens, while opening doors to greater investment in research, innovation, and product development.
Despite the optimism, some companies remain cautious. Village Farms International, which trades on Nasdaq under the ticker VFF but is incorporated in Canada, continues to focus on international markets until U.S. regulations become clearer. CEO Michael DeGiglio emphasizes the importance of collaborating with policymakers to shape sensible rules before committing significant resources domestically.
Overall, the rescheduling executive order is seen as a pivotal step toward broader acceptance of cannabis as a legitimate agricultural and medical product. Stakeholders agree that while the immediate benefits—tax relief, improved banking, and increased investor interest—are tangible, success will depend on how quickly businesses can adapt to the evolving compliance landscape and invest in the scientific rigor needed to meet future federal standards.
For more details on the announcement and its industry impact, see the original coverage Here.
